Developer · 3692.HK · China

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Operating company of Hansoh Pharmaceutical Group Company Limited (HKEX: 3692), a Chinese innovative-drug company whose focus areas include oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Registered sponsor of all ClinicalTrials.gov studies of obuprazine (HS-10380) in schizophrenia.

hspharm.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 0 upcoming · 1 reported

Recently reported

  • 2026-10-10met

    Obuprazine (HS-10380)forSchizophreniaFull results

    Phase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.

    source ↗

Recent activity

  • Oct 10, 2026ReadoutObuprazine (HS-10380)·SchizophreniametPhase 2b of obuprazine (HS-10380) in acute schizophrenia met its primary endpoint: all three dose ranges beat placebo on PANSS total change at Day 42 (LSMD -16.7, -13.2, -14.7; aripiprazole -12.1); presented at ECNP 2026.source ↗
  • May 23, 2024Phase changeObuprazine (HS-10380)·SchizophreniaPhase 2Phase 2b in hospitalized adults with acute schizophrenia (NCT07550387, HS-10380-202) started (actual date per ClinicalTrials.gov); primary completion 2026-01-02, study completion 2026-01-19. Registered retrospectively (first posted 2026-04-24).source ↗
  • Jul 30, 2023Phase changeObuprazine (HS-10380)·SchizophreniaPhase 1/2Phase 1b/2 in Chinese adults with schizophrenia (NCT05964790, HS-10380-201) registered with an ESTIMATED start of 2023-07-30; the record was never updated (status UNKNOWN), so the date is approximate.source ↗
  • Aug 1, 2022Phase changeObuprazine (HS-10380)·SchizophreniaPhase 1First-in-human SAD/MAD study in Chinese healthy adults (NCT05480592, HS-10380-101) started per ClinicalTrials.gov (registered under schizophrenia; record status since UNKNOWN).source ↗

Trials recruiting · 1 recruiting of 13 sponsored

  • Phase 3HS-10506, Placebon=732

    A Study of HS-10506 in Chinese Patients With Insomnia Disorder

    Insomnia DisorderNCT07587385 ↗

Competitive landscape

Other companies developing against Jiangsu Hansoh Pharmaceutical Co., Ltd.'s targets or indications.